PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19766187-10 2009 K combined with a half-dose of FK-506 reduced the expression levels of IL-2 and IFN-gamma (both within the graft and in the recipients" serum) more effectively than a full-dose of FK-506. Tacrolimus 31-37 interleukin 2 Mus musculus 71-75 28522399-7 2017 Sacran solutions and 0.1%Tacrolimus reduced disease severity, suppressed histological changes and decreased the serum Th-1 (IFN-gamma, TNF-alpha, IL-2) and Th-2 (IL-4, IL-6, IL-10) cytokines in allergic mice (vs. controls). Tacrolimus 25-35 interleukin 2 Mus musculus 146-150 25770929-4 2015 It was observed that topical administration of tacrolimus significantly accelerated the tumor promotion events in dimethylbenz(a)anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA) promoted two-stage mouse skin carcinogenesis, which were accompanied by reduced CD4(+)/CD8(+) ratio of lymph nodes and serum IL-2 level. Tacrolimus 47-57 interleukin 2 Mus musculus 329-333 25333459-8 2015 IL-2 expression was increased in the allogeneic acute rejection group and was inhibited in mice treated with CsA and FK506. Tacrolimus 117-122 interleukin 2 Mus musculus 0-4 23390586-1 2013 FK506 (Tacrolimus) is a potent inhibitor of calcineurin that blocks IL2 production and is widely used to prevent transplant rejection and treat autoimmunity. Tacrolimus 0-5 interleukin 2 Mus musculus 68-71 23390586-1 2013 FK506 (Tacrolimus) is a potent inhibitor of calcineurin that blocks IL2 production and is widely used to prevent transplant rejection and treat autoimmunity. Tacrolimus 7-17 interleukin 2 Mus musculus 68-71 19627009-6 2009 Simultaneously, the level of IL-2 and IL-4 in leukemia mice treated with FK506 and CSA decreased significantly than those of intact or leukemia control mice. Tacrolimus 73-78 interleukin 2 Mus musculus 29-33 19627009-7 2009 CONCLUSION: FK506 can promote the survival of HSCs in host, and the mechanism may be associated with the down regulation of IL-2 and IL-4. Tacrolimus 12-17 interleukin 2 Mus musculus 124-128 10798785-9 2000 CONCLUSION: FK506 protects against allograft rejection by inhibiting interleukin-2 production. Tacrolimus 12-17 interleukin 2 Mus musculus 69-82 18656798-9 2008 Tacrolimus prophylaxis was associated with inhibition of recruitment of CD4+, CD8+ and interleukin-2R+ inflammatory cells into the allografts, suggesting a central role for interleukin-2 in the development of OAD. Tacrolimus 0-10 interleukin 2 Mus musculus 87-100 15919519-8 2005 CsA, MMF, and AS-ODNs inhibited MD-1 expression and lymphocyte proliferation, as well as decreased serum level of IL-2 and increased that of IL-10; FK506, treatment showed all the effects mentioned above but up-regulated the IL-10 level; SRL had no significant influence on either MD-1 expression or IL-2 and IL-10 level, although it equally suppressed the proliferation (P < .05 vs controls). Tacrolimus 148-153 interleukin 2 Mus musculus 114-118 15919519-8 2005 CsA, MMF, and AS-ODNs inhibited MD-1 expression and lymphocyte proliferation, as well as decreased serum level of IL-2 and increased that of IL-10; FK506, treatment showed all the effects mentioned above but up-regulated the IL-10 level; SRL had no significant influence on either MD-1 expression or IL-2 and IL-10 level, although it equally suppressed the proliferation (P < .05 vs controls). Tacrolimus 148-153 interleukin 2 Mus musculus 300-304 11935154-9 2002 Islet grafts from sirolimus plus tacrolimus-treated mice expressed significantly decreased mRNA contents of Th1-type cytokines (IFN- gamma and IL-2) and the highest ratio of TGF- beta1/IFN- gamma mRNA. Tacrolimus 33-43 interleukin 2 Mus musculus 143-147 11935154-10 2002 CONCLUSION/INTERPRETATION: These findings suggest that combination therapy with sirolimus and tacrolimus prevent autoimmune beta-cell destruction by upregulating expression of the immunoregulatory cytokine, TGF- beta1 and reducing Th1 cytokines (IFN- gamma and IL-2) expressed in the islets. Tacrolimus 94-104 interleukin 2 Mus musculus 261-265 8986461-1 1996 FK-506 (Tacrolimus) has been shown to block T cell proliferation in vitro by inhibiting the generation of several lymphokines, especially interleukin (IL)-2, but little direct evidence is available to support the view that the immunosuppressive effects of FK-506 in vivo are mediated by a similar inhibition of lymphokine cascade. Tacrolimus 0-6 interleukin 2 Mus musculus 138-156 9605132-6 1998 Further analysis of the LNC cytokine pattern revealed that the production of both Thl (IFN-gamma and IL-2) and Th2 (IL-4) cytokines was dramatically impaired after topical FK506 treatment. Tacrolimus 172-177 interleukin 2 Mus musculus 101-105 9566798-6 1998 Hapten-immune lymph node cells from mice treated in vivo with CsA or FK506 failed to proliferate and to produce IL-2 when re-exposed to the specific antigen in vitro. Tacrolimus 69-74 interleukin 2 Mus musculus 112-116 9336339-6 1997 Contrary to the above in vivo findings, the immunosuppressors, FK-506 and cyclosporin A, inhibited the production of interferon-gamma and interleukin-2 by cultured Th1 cells (1E10.H2 cells) and of interleukin-4 and -5 by Th2 cells (D10.G4.1 cells) in vitro. Tacrolimus 63-69 interleukin 2 Mus musculus 138-151 8986461-1 1996 FK-506 (Tacrolimus) has been shown to block T cell proliferation in vitro by inhibiting the generation of several lymphokines, especially interleukin (IL)-2, but little direct evidence is available to support the view that the immunosuppressive effects of FK-506 in vivo are mediated by a similar inhibition of lymphokine cascade. Tacrolimus 8-18 interleukin 2 Mus musculus 138-156 8986461-6 1996 In contrast to the effects of FK-506 on IL-2 and IFN-gamma productions in MLN, IL-1 and tumor necrosis factor-alpha in the intestinal wall, which were enhanced by H. nana infection, were not completely decreased as a result of 10.0 mg/kg FK-506 treatment. Tacrolimus 30-36 interleukin 2 Mus musculus 40-44 8986461-7 1996 The reverse transcriptase-PCR revealed complete inhibition of IL-2 and IFN-gamma mRNA expression on mesenteric L3T4+ cells that were induced by H. nana infection, when mice were given 10.0 mg/kg/day FK-506 for 5 days. Tacrolimus 199-205 interleukin 2 Mus musculus 62-66 8617295-7 1996 B7-1 stimulation is not mediated by the enhancement of IL-2 production: B7-1 enhancement of IL-2R alpha expression was FK506 resistant, while the inclusion of FK506 abrogated IL-2 production of the Th1 cells. Tacrolimus 119-124 interleukin 2 Mus musculus 92-96 1702375-6 1990 Either CyA or FK506 significantly reduced the number of cells expressing OX-39 (interleukin-2 receptors) and OX-40. Tacrolimus 14-19 interleukin 2 Mus musculus 80-93 7530743-1 1995 FK506 and cyclosporin A (CsA) are immunosuppressive agents that inhibit IL-2 production by activated T cells, but only CsA inhibits IgE activation-induced cytokine transcripts in mouse IL-3-dependent, bone marrow-derived mast cells (BMMC). Tacrolimus 0-5 interleukin 2 Mus musculus 72-76 7692640-2 1993 FK-506 is known to suppress the transcription of several genes encoding cytokines (e.g., IL-2, IFN-gamma) thought to play an important role in the allograft response. Tacrolimus 0-6 interleukin 2 Mus musculus 89-93 7692640-12 1993 Therefore, the ability of FK-506 to differentially suppress the mRNA levels of immunostimulatory cytokines such as IL-2, IL-4, and IFN-gamma more than the mRNA levels of the immunosuppressive cytokine IL-10 suggests that the effective immunosuppression seen in vivo with FK-506 may be a combination of these 2 effects. Tacrolimus 26-32 interleukin 2 Mus musculus 115-119 7875200-7 1995 The immunosuppressant FK506 as well as dominant negative alleles of Ras and Raf inhibited HamT-induced IL-2 transcription. Tacrolimus 22-27 interleukin 2 Mus musculus 103-107 7682200-0 1993 Regulation of liver regeneration by interleukin-2 and its inhibitors: cyclosporine A and FK 506. Tacrolimus 89-95 interleukin 2 Mus musculus 36-49 7682200-6 1993 On the other hand, treatment with CsA and FK506, which inhibit IL-2 production, increased the mitotic indices of the regenerating livers. Tacrolimus 42-47 interleukin 2 Mus musculus 63-67 7682200-8 1993 Based on these results, CsA and FK506 would appear to stimulate liver cell proliferation by suppressing IL-2 production and inhibiting of NK cell activity. Tacrolimus 32-37 interleukin 2 Mus musculus 104-108 1384815-1 1992 The immunosuppressive drugs FK506 and cyclosporin A have an identical spectrum of activities with respect to IgE receptor (Fc epsilon RI)-mediated exocytosis from mast cells and T cell receptor-mediated transcription of IL-2. Tacrolimus 28-33 interleukin 2 Mus musculus 220-224 1371158-7 1992 Similarly, FK506 completely inhibited cytokine production by MC/9, partially inhibited cytokine production by MCIII and had differential effects on IL-3/granulocyte-macrophage colony-stimulating factor and IL-2/IL-4 production by MCVI. Tacrolimus 11-16 interleukin 2 Mus musculus 206-210 1689353-2 1990 FK-506 acts similarly to cyclosporin A (CsA) and prevents IL-2 production and IL-2R expression. Tacrolimus 0-6 interleukin 2 Mus musculus 58-62 1696410-8 1990 Exogenous IL-2 or L3T4+ T cells could overcome the immunosuppressive effect of FK506 on the CTL induction of Ly2+ T cells in a secondary MLC. Tacrolimus 79-84 interleukin 2 Mus musculus 10-14 1689353-9 1990 In one such model, the stimulation of splenic T cells with IL-2 + PMA, FK-506, but not CsA, reversed the suppressive effect of RAP on proliferation. Tacrolimus 71-77 interleukin 2 Mus musculus 59-63 1688572-3 1990 FK-506 or CsA also inhibited proliferation, IL-2 production, and IL-2R expression in splenic T cells activated with ionomycin + PMA. Tacrolimus 0-6 interleukin 2 Mus musculus 44-48 1688572-10 1990 Finally, T cell proliferation driven by IL-2 or IL-4 was found to be relatively resistant to FK-506 or CsA but sensitive to RAP. Tacrolimus 93-99 interleukin 2 Mus musculus 40-44 1689226-8 1990 FK-506 also suppressed increases in the small proportion of blood-borne OX-40+ (activated CD4+) cells and OX-39+ (interleukin-2 receptor+) cells in the 7 day period following immunization; thereafter values for activation marker expression between treatment and control groups were similar. Tacrolimus 0-6 interleukin 2 Mus musculus 114-127 34144106-4 2021 Among many immunosuppressants, tacrolimus (FK506) is one of the most potent interleukin-2 (IL-2)-mediated T-cell proliferation blockers. Tacrolimus 31-41 interleukin 2 Mus musculus 76-89 34144106-4 2021 Among many immunosuppressants, tacrolimus (FK506) is one of the most potent interleukin-2 (IL-2)-mediated T-cell proliferation blockers. Tacrolimus 31-41 interleukin 2 Mus musculus 91-95 34144106-4 2021 Among many immunosuppressants, tacrolimus (FK506) is one of the most potent interleukin-2 (IL-2)-mediated T-cell proliferation blockers. Tacrolimus 43-48 interleukin 2 Mus musculus 76-89 34144106-4 2021 Among many immunosuppressants, tacrolimus (FK506) is one of the most potent interleukin-2 (IL-2)-mediated T-cell proliferation blockers. Tacrolimus 43-48 interleukin 2 Mus musculus 91-95 2442255-8 1987 On the other hand, it was found that FK506 inhibited both IL-2 secretion and IL-2 receptor expression of BC.21 after stimulation with the specific antigen. Tacrolimus 37-42 interleukin 2 Mus musculus 58-62 2442255-8 1987 On the other hand, it was found that FK506 inhibited both IL-2 secretion and IL-2 receptor expression of BC.21 after stimulation with the specific antigen. Tacrolimus 37-42 interleukin 2 Mus musculus 77-81